Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Professor of Infectious Diseases



+44 (0)20 7594 3903g.cooke




Infectious Diseases SectionWinston Churchill WingSt Mary's Campus





Graham Cooke is NIHR Research Professor of Infectious Diseases based within the  the Wright-Fleming Institute at Imperial College. He trained in Oxford, London and South Africa. Prior to joining Imperial he was based at the Africa Health Research Institute in KwaZulu-Natal.

His current work is focussed on precision medicine for management of infectious diseases, particularly for HIV/viral hepatitis, mycobacterial disease and acute infection. From 2011-19, he led the clinical workstream for the MRC Stratified Medicine Consortium (STOPHCV) and is infection lead for the London In-vitro diagnostics co-operative. He was chief investigator on the STOPHCV-1 trial and currently has clinical studies running in the UK and Vietnam, in collaboration with the MRC Clinical Trials Unit. 

He is active in promoting access to medicine and is chair of the WHO Committee on the Selection and Use of Essential Medicines, responsible for updating and maintaining the WHO Essential Medicines List (EML). He led the Commission on Accelerating the Elimination of Viral Hepatitis, published here, and in 2019 was appointed to the Expert groups in HIV and hepatitis (the latter as convenor) for the Infected Blood Inquiry

Funding: NIHR, Wellcome Trust, MRC, Médecins sans Frontières, BRC Imperial College


Follow on twitter: @grahamscooke

Selected Publications

Journal Articles

Simmons B, Cooke GS, Miraldo M, 2019, Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis, The Lancet Global Health, Vol:7, ISSN:2214-109X, Pages:e1189-e1196

Heffernan A, Cooke G, Nayagam S, et al., 2019, Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, The Lancet, Vol:393, ISSN:0140-6736, Pages:1319-1329

Cooke GS, Andrieux-Meyer I, Applegate TL, et al., 2019, Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184

Ansari A, Pedergnana V, Ip C, et al., 2017, Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus, Nature Genetics, Vol:49, ISSN:1546-1718, Pages:666-673

Cooke GS, Gurrala R, Harrison E, et al., 2016, Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia, Scientific Reports, Vol:6, ISSN:2045-2322

Stanaway JD, Flaxman AD, Naghavi M, et al., 2016, The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, The Lancet, Vol:388, ISSN:0099-5355, Pages:1081-1088

Simmons B, Saleem J, Hill A, et al., 2016, Risk of late relapse or reinfection with Hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis, Clinical Infectious Diseases, Vol:62, ISSN:1537-6591, Pages:683-694

Simmons B, Saleem J, Heath K, et al., 2015, Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response, Clinical Infectious Diseases, Vol:61, ISSN:1537-6591, Pages:730-740

Rao VB, Johari N, duCros P, et al., 2015, Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis, Lancet Infectious Diseases, ISSN:1473-3099

van de Ven N, Fortunak J, Simmons B, et al., 2015, Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus, Hepatology, Vol:61, ISSN:1527-3350, Pages:1174-1182

Messina JP, Humphreys I, Flaxman A, et al., 2014, Global Distribution and Prevalence of Hepatitis C Virus Genotypes, Hepatology

Hill AM, Cooke GS, 2014, Hepatitis C can be cured globally, but at what cost?, Science, Vol:345, Pages:141-142

More Publications